title: Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
authors.affiliation: British Columbia Cancer Agency, Vancouver, BC, Canada. kgelmon@bccancer.bc.ca
authors.forename: K A
authors.initials: KA
authors.lastname: Gelmon
authors.forename: E A
authors.initials: EA
authors.lastname: Eisenhauer
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
authors.forename: M J
authors.initials: MJ
authors.lastname: Ratain
authors.forename: P
authors.initials: P
authors.lastname: Workman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015507:Drugs, Investigational / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational